It has a strong antibacterial effect on most anaerobic bacteria, including Bacteroides fragilis and other Bacteroides, Fusobacterium, Clostridium perfringens, Eubacterium, Veillonella, Peptococcus and Peptostreptococcus; it inhibits the redox reaction of amoeba and breaks the nitrogen chain of the protozoa; it has a strong effect of killing Trichomonas.

According to the requirements of the "Non-clinical Research Management Standards for Drugs" and relevant national guidelines for preclinical research of new drugs, experiments on mice, guinea pigs and cats showed that: no abnormal toxic reactions and deaths were observed in mice within 48 hours after injection; the antihypertensive substance inspection was in compliance with the pharmacopoeia regulations; the activity, food intake, water drinking and weight gain of guinea pigs were not affected in the sensitization test, and there were no allergic reactions or deaths; and no abnormal reactions and deaths were observed in ICR mice after intravenous injection of large doses.

(1) According to the requirements of the "Non-clinical Drug Research Management Standards" and the relevant guidelines for preclinical research of new drugs in the country, the product was injected into mice at a dose of 0.8 ml/mouse. No abnormal toxic reaction or death was observed within 48 hours after injection. The abnormal toxicity test results for mice were qualified. (2) According to the method requirements for the antihypertensive substance test in the appendix of the "Pharmacopoeia of the People's Republic of China", this product was tested for antihypertensive substances in cats, and the results met the antihypertensive substance requirements specified in the Pharmacopoeia. (3) According to the requirements of the "Non-clinical Drug Research Management Standards" and the relevant guidelines for preclinical research of new drugs in China, the product was injected intraperitoneally into healthy white Hautley guinea pigs, 0.5 ml per guinea pig, once every other day, for 3 consecutive times for sensitization. The results showed that the product had no effect on the activity, food intake, and drinking water of guinea pigs, and had no significant effect on the weight gain of guinea pigs. No abnormal reactions occurred during the test, and no guinea pigs died. The incidence rate and mortality rate of allergic reactions were both 0.4) According to the requirements of the "Non-clinical Drug Research Management Standards" and the relevant guidelines for preclinical research of new drugs in China, the product was injected intravenously into healthy clean-grade ICR mice at a dose of 100 ml/kg. After administration, no abnormal reactions were observed in male and female mice, and no animal deaths were caused. The maximum dosage for mice is greater than 100 ml/kg.

(1) According to the requirements of the "Non-clinical Drug Research Management Standards" and the relevant guidelines for preclinical research of new drugs in the country, the product was injected into mice at a dose of 0.8 ml/mouse. No abnormal toxic reaction or death was observed within 48 hours after injection. The abnormal toxicity test results for mice were qualified. (2) According to the method requirements for the antihypertensive substance test in the appendix of the "Pharmacopoeia of the People's Republic of China", this product was tested for antihypertensive substances in cats, and the results met the antihypertensive substance requirements specified in the Pharmacopoeia. (3) According to the requirements of the "Non-clinical Drug Research Management Standards" and the relevant guidelines for preclinical research of new drugs in China, the product was injected intraperitoneally into healthy white Hautley guinea pigs, 0.5 ml per guinea pig, once every other day, for 3 consecutive times for sensitization. The results showed that the product had no effect on the activity, food intake, and drinking water of guinea pigs, and had no significant effect on the weight gain of guinea pigs. No abnormal reactions occurred during the test, and no guinea pigs died. The incidence rate and mortality rate of allergic reactions were both 0.4) According to the requirements of the "Non-clinical Drug Research Management Standards" and the relevant guidelines for preclinical research of new drugs in China, the product was injected intravenously into healthy clean-grade ICR mice at a dose of 100 ml/kg. After administration, no abnormal reactions were observed in male and female mice, and no animal deaths were caused. The maximum dosage for mice is greater than 100 ml/kg.

Nonsteroidal antipyretic analgesic drugs may produce analgesic and antipyretic effects mainly by inhibiting the synthesis of prostaglandins. It has analgesic synergistic effects with chlorzoxazone.

Central skeletal muscle relaxants mainly act on the spinal cord and subcortical centers of the brain to inhibit the polysynaptic reflexes associated with muscle spasms, thereby producing a muscle relaxant effect, relieving pain caused by spasms and increasing the flexibility of the affected muscles. Its effect can be enhanced when used in combination with acetaminophen.

It improves blood rheology by reducing blood viscosity, reduces blood viscosity in a dose-dependent manner, improves red blood cell deformability, improves the blood rheological properties of white blood cells, and inhibits the adhesion and activation of neutrophils. For patients with chronic peripheral arterial vascular disease, it can increase blood flow, affect microcirculation, and improve tissue oxygen supply.

Extract from the above information